Overview

Exogenous Melatonin in Postmenopausal Women With Insomnia

Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to assess the effect of exogenous melatonin, 2 mg SR, 60 minutes before bedtime for 15 days, on the sleep and circadian rhythms of postmenopausal women with insomnia in a randomized crossover placebo-controlled study.
Phase:
N/A
Details
Lead Sponsor:
Douglas Mental Health University Institute
Collaborator:
Canadian Institutes of Health Research (CIHR)
Treatments:
Melatonin